{"groups":[{"description":"VELCADE, Lenalidomide, Dexamethasone\n\nVELCADE: 1.3 mg/m2 by IV on days 1, 4, 8, 11 of each cycle\n\nLenalidomide: 25 mg by mouth on days 1-4 of each cycle\n\nDexamethasone: 20 mg the day before and the day after receiving VELCADE\n\nDVT prophylaxis: At least one asprin 81 mg per day. Other option per physician's choice\n\nBisphosphonates: Zoledronic acid by IB or pamidronate by IV can be used as per standard of care.","id":"FG000","title":"VRD (VELCADE, Lenalidomide, Dexamethasone)"},{"description":"VELCADE, liposomal doxorubicin, dexamethasone\n\nVELCADE: 1.3 mg/m2 by IV on days 1, 4, 8, 11 of each cycle\n\nDVT prophylaxis: At least one asprin 81 mg per day. Other option per physician's choice\n\nLiposomal doxorubicin: 30 mg/m2 on day 4 of each cycle\n\nDexamethasone: 40 mg by mouth on days 1-4, 8-11, and 15-18 of cycle 1 and days 1-4 on cycle 2-4","id":"FG001","title":"VDD (VELCADE, Liposomal Doxorubicin, Dexamethasone)"}],"periods":[{"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"33"},{"groupId":"FG001","numSubjects":"3"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"23"},{"groupId":"FG001","numSubjects":"3"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"10"},{"groupId":"FG001","numSubjects":"0"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"recruitmentDetails":"Participants participated in this trial at Vanderbilt-Ingram Cancer Center in Nashville, TN and the Boston Baskin Cancer Group in Memphis, TN. A total of 52 people consented to take part in this study and 15 were ineligible. One participant had disease progression before beginning treatment and wasn't assigned to a treatment arm."}